Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

NCT06518837 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hormone Receptor-Positive Breast Cancer
HER2-Negative Breast Cancer

Interventions

DRUG: Tirzepatide

Sponsor

Rutgers, The State University of New Jersey

Collaborators

[object Object]